Skip to main content
SpringerLink
Log in

First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation

  • Letter to the Editor
  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Rivaroxaban and apixaban are direct oral anticoagulants whose target specificity is to activate factor X (FXa). It is still not fully understood how xabans impact platelet function. This single-center observational study aimed to assess in vitro platelet function in patients with atrial fibrillation receiving rivaroxaban or apixaban. It examined quantification of platelet aggregation assessed by light transmission aggregometry in thirty-four patients treated with apixaban or rivaroxaban. The thrombin-induced platelet aggregation was significantly lower 2 h after taking selected xabans compared to baseline value (69.55 ± 32.15% vs. 44.79 ± 34.97.9%; p < 0.0001). This effect was only observed in patients who received rivaroxaban or apixaban for more than 1 week. The thrombin-induced platelet aggregation is reduced in cardiovascular patients receiving rivaroxaban or apixaban. This reduction is likely to depend on the duration of the treatment. Duration of treatment should be considered in future studies focusing on DOACs and platelet aggregation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Vinholt PJ, Nielsen C, Söderström AC, Brandes A, Nybo M (2017) Dabigatran reduces thrombin-induced platelet aggregation and activation in a dose-dependent manner. J Thromb Thrombolysis 44:216–222

    Article  PubMed  CAS  Google Scholar 

  2. Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ et al (1988) The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 71:335–343

    PubMed  CAS  Google Scholar 

  3. Sadeghi N, Kahn D, Jeske W, Hoppensteadt D, Fareed J (2013) Tissue factor-mediated activation of the prothrombin complex concentrate (PCC) is differently inhibited by dabigatran, rivaroxaban, and apixaban: potential clinical implication. Clin Appl Thromb Hemost 19:589–599

    Article  PubMed  CAS  Google Scholar 

  4. Davey MG, Luscher EF (1967) Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature 216:857–858

    Article  PubMed  CAS  Google Scholar 

  5. Harrison P, Mackie I, Mumford A, Briggs C, Liesner R, Winter M, Machin S (2011) British Committee for Standards in Haematology. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 155:30–44

    Article  PubMed  CAS  Google Scholar 

  6. Nehaj F, Sokol J, Ivankova J, Mokan M, Kovar F, Stasko J, Mokan M (2017) First evidence: TRAP-induced platelet aggregation is reduced in patients receiving Xabans. Clin Appl Thromb Hemost. https://doi.org/10.1177/1076029617734310

    Article  PubMed  Google Scholar 

  7. Nehaj F, Sokol J, Mokan M, Ivankova J, Mokan M (2017) Thrombin receptor agonist peptide-induced platelet aggregation is reduced in patients receiving dabigatran. Clin Appl Thromb Hemost. https://doi.org/10.1177/1076029617713871

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The study was supported by the VEGA 1/0187/17 grant.

Author information

Authors and Affiliations

  1. Department of Haematology and Transfusion Medicine, National Centre of Haemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59, Martin, Slovakia

    Juraj Sokol & Jela Ivankova

  2. First Department of Internal Medicine, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59, Martin, Slovakia

    Frantisek Nehaj, Michal Mokan & Marian Mokan

Authors
  1. Juraj Sokol
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frantisek Nehaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jela Ivankova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michal Mokan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marian Mokan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frantisek Nehaj.

Ethics declarations

Conflicting of interest

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional review board and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from patients described in this report.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sokol, J., Nehaj, F., Ivankova, J. et al. First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation. J Thromb Thrombolysis 46, 393–398 (2018). https://doi.org/10.1007/s11239-018-1709-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-018-1709-z

Keywords

Search

Navigation